By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as ...

Explore the future of the Chronic Obstructive Pulmonary Disease (COPD) market with our comprehensive report. This forecast model covers the 7 major markets from 2023 to 2033, predicting a CAGR of 10%, ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.

A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

A new study published in the International Journal of Chronic Obstructive Pulmonary Disease showed that regardless of ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a recent study.

The class, which is free to participate in, takes place from 6PM to 7:30 PM Thursday night via ZOOM. The class aims to teach ...